[1]
|
D. Grimwade, H. Walker, G. Harrison, et al., “The Predictive Value of Hierarchical Cytogenetic Classification in Older Adults with Acute Myeloid Leukemia (AML): Analysis of 1065 Patients Entered into the United Kingdom Medical Research Council AML 11 Trial,” Blood, Vol. 98, No. 5, 2001, pp. 1312-1320.
doi:10.1182/blood.V98.5.1312
|
[2]
|
P. D. Kottaridis and R. E. Gale, Frew “The Presence of a FLT3 Internal Tandem Duplication in Patients with Acute Myeloid Leukemia (AML) Adds Important Prognostic Information to Cytogenetic Risk Group and Response to the First Cycle of Chemotherapy: Analysis of 854 Patients from the United Kingdom Medical Research Council AML 10 and 12 Trials,” Blood, Vol. 98, No. 6, 2001, pp. 1752-1759. doi:10.1182/blood.V98.6.1752
|
[3]
|
M. A. Sekeres, P. Elson, M. E. Kaylacio, et al., “Time from Diagnosis to Treatment Initiation Predicts Survival in Younger, But Not Older, Acute Myeloid Leukemia Patients,” Blood, Vol. 113, No. 1, 2009, pp. 28-36.
doi:10.1182/blood-2008-05-157065
|
[4]
|
E. M. Fagundes, V. Rocha and A. B. Glória, et al., “De Novo Acute Myeloid Leukemia in Adults Younger than 60 Years of Age: Socioeconomic Aspects and Treatment Results in a Brazilian University Center,” Leukemia & Lymphoma, Vol. 47, No. 8, 2006, pp. 1557-1564.
doi:10.1080/10428190600627055
|
[5]
|
W. Pulcheri, N. Spector, M. Nucci, et al., “The Treatment of Acute Myeloid Leukemia in Brazil: Progress and Obstacles,” Haematologica, Vol. 80, No. 2, 1995, pp. 130-135.
|
[6]
|
L. A. Pelloso, M. de L. Chauffaille, F. S. Ghaname, et al., “Karyotype in Acute Myeloid Leukemia: Importance and Type of Aberrations in 30 Patients at Diagnosis,” Revista da Associa??o Médica Brasileira, Vol. 49, No. 2, 2003, pp. 150-155. doi:10.1590/S0104-42302003000200032
|
[7]
|
C. A. Rodrigues, M. L. Chauffaille, L. A. Pelloso, et al., “Acute Myeloid Leukemia in Elderly Patients: Experience of a Single Center,” Brazilian Journal of Medical and Biological Research, Vol. 36, No. 6, 2003, pp. 703-708. doi:10.1590/S0100-879X2003000600004
|
[8]
|
A. Kanamaru, Y. Takemoto, M. Tanimoto, H. Muramaki, N. Asou, T. Kobayashi, K. Kuriyama, E. Ohmoto, H. Sakamaki, K. Tsubari, A. Hiraoka, O. Yamada, H. Oh, K. Saito, S. Matsuda, K. Minato, T. Ueda, O. Ohno and Japan Study Group, “All Trans Retinoic Acid for the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia,” Blood, Vol. 85, No. 5, 1995, pp. 1202-1206.
|
[9]
|
F. R. Appelbaum, H. Gundacker, D. R. Head, et al., “Age and Acute Myeloid Leukemia,” Blood, Vol. 107, No. 9, 2006, pp. 3481-3485. doi:10.1182/blood-2005-09-3724
|
[10]
|
G. Juliusson, et al., “Most 70-to 79-Year-Old Patients with Acute Myeloid Leukemia Do Benefit from Intensive Treatment,” Blood, Vol. 117, No. 12, 2011, pp. 3473-3474. doi:10.1182/blood-2010-11-321737
|